Topaly J - Search Results

1

Rationale for combination therapy of chronic myelogenous leukaemia with imatinib and irradiation or alkylating agents: implications for pretransplant conditioning.

Topaly J, Fruehauf S, Ho AD, Zeller WJ. Topaly J, et al. Br J Cancer. 2002 May 6;86(9):1487-93. doi: 10.1038/sj.bjc.6600242. Br J Cancer. 2002. PMID: 11986785 Free PMC article.

2

Combination treatment of imatinib-sensitive and -resistant BCR-ABL-positive CML cells with imatinib and farnesyltransferase inhibitors.

Radujkovic A, Topaly J, Fruehauf S, Zeller WJ. Radujkovic A, et al. Among authors: topaly j. Anticancer Res. 2006 May-Jun;26(3A):2169-77. Anticancer Res. 2006. PMID: 16827161 Free article.

3

Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis.

Fruehauf S, Topaly J, Buss EC, Fischer T, Ottmann OG, Emmerich B, Müller MC, Schuld P, Balleisen L, Hehlmann R, Ho AD, Hochhaus A. Fruehauf S, et al. Among authors: topaly j. Cancer. 2007 Apr 15;109(8):1543-9. doi: 10.1002/cncr.22535. Cancer. 2007. PMID: 17340589 Free article. Clinical Trial.

4

Synergistic activity of nilotinib and established chemotherapeutic drugs in imatinib-sensitive and -resistant BCR-ABL-positive cells.

Radujkovic A, Fruehauf S, Zeller WJ, Ho AD, Topaly J. Radujkovic A, et al. Among authors: topaly j. Cancer Chemother Pharmacol. 2010 Jul;66(2):255-64. doi: 10.1007/s00280-009-1158-7. Epub 2009 Oct 28. Cancer Chemother Pharmacol. 2010. PMID: 19862526

5

In vitro testing of drug combinations employing nilotinib and alkylating agents with regard to pretransplant conditioning treatment of advanced-phase chronic myeloid leukemia.

Radujkovic A, Luft T, Dreger P, Ho AD, Jens Zeller W, Fruehauf S, Topaly J. Radujkovic A, et al. Among authors: topaly j. Cancer Chemother Pharmacol. 2014 Aug;74(2):427-32. doi: 10.1007/s00280-014-2533-6. Epub 2014 Jul 20. Cancer Chemother Pharmacol. 2014. PMID: 25038611

6

Peripheral blood progenitor cell (PBPC) counts during steady-state haemopoiesis enable the estimation of the yield of mobilized PBPC after granulocyte colony-stimulating factor supported cytotoxic chemotherapy: an update on 100 patients.

Fruehauf S, Schmitt K, Veldwijk MR, Topaly J, Benner A, Zeller WJ, Ho AD, Haas R. Fruehauf S, et al. Among authors: topaly j. Br J Haematol. 1999 Jun;105(3):786-94. doi: 10.1046/j.1365-2141.1999.01405.x. Br J Haematol. 1999. PMID: 10354148 Free article.

7

Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells.

Topaly J, Zeller WJ, Fruehauf S. Topaly J, et al. Leukemia. 2001 Mar;15(3):342-7. doi: 10.1038/sj.leu.2402041. Leukemia. 2001. PMID: 11237055 Clinical Trial.

8

Pulmonary artery hypertension during interferon-alpha therapy for chronic myelogenous leukemia.

Fruehauf S, Steiger S, Topaly J, Ho AD. Fruehauf S, et al. Among authors: topaly j. Ann Hematol. 2001 May;80(5):308-10. doi: 10.1007/s002770100298. Ann Hematol. 2001. PMID: 11446736

9

Combination therapy with imatinib mesylate (STI571): synopsis of in vitro studies.

Topaly J, Zeller WJ, Fruehauf S. Topaly J, et al. Br J Haematol. 2002 Oct;119(1):3-14. doi: 10.1046/j.1365-2141.2002.03806.x. Br J Haematol. 2002. PMID: 12358898 Free article. Review. No abstract available.

10

Imatinib restores expression of CD62L in BCR-ABL-positive cells.

Fruehauf S, Topaly J, Schad M, Paschka P, Gschaidmeier H, Zeller WJ, Hochhaus A, Ho AD. Fruehauf S, et al. Among authors: topaly j. J Leukoc Biol. 2003 May;73(5):600-3. doi: 10.1189/jlb.1002507. J Leukoc Biol. 2003. PMID: 12714574

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

27 results

Search Page